U. Praturi

Protective efficacy of Zika vaccine in AG129 mouse model

K. Sumathy, K. Ella, B. Kulkarni, 2017, Scientific Reports.

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

K. Ella, S. Panda, G. Sapkal, 2021, The Lancet Infectious Diseases.

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report

K. Ella, S. Panda, G. Sapkal, 2020, medRxiv.

Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial

K. Ella, P. Yadav, P. Abraham, 2022, medRxiv.